Gilead Sciences Announces Fourth Quarter and Full Year 2013 Financial Results Business Wire (press release) The recommendation followed a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free survival in patients receiving idelalisib plus rituximab compared to those receiving rituximab ... |
